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ABSTRACT:  
Entecavir (BMS-200475) was synthesized from 4-trimethylsilyl-3-butyn-2-one and acrolein. The key 
features of its preparation are: (i) a stereoselective boron-aldol reaction to afford the acyclic carbon 
skeleton of the methylenecylopentane moiety; (ii) its cyclization by a Cp2TiCl-catalyzed intramolecular 
radical addition of an epoxide to an alkyne; and (iii) the coupling with a purine derivative by a 
 
2 
Mitsunobu reaction. 
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Introduction 
B-type hepatitis is a global disease. It is one of the most common viral infections worldwide despite an 
efficient vaccine being available since 1982. According to the World Health Organization (WHO) about 
two billion people are infected worldwide and 600,000 die every year due to consequences such as 
cirrhosis of the liver or liver cancer. Hepatitis B can manifest itself in both acute and chronic forms and 
is especially dangerous in children. About 90% of infants infected during the first year of life develop 
chronic infections, although this ratio drops to 30-50% in children infected between the ages of one and 
four. About 25% of adults who become chronically infected during childhood will die from hepatitis B-
related liver cancer or cirrhosis while about 90% of people who become infected during adulthood will 
recover and be completely free of the virus within six months. About 240 million people are thought to 
be chronically infected with the disease worldwide.1 
In its chronic form hepatitis B can be treated with interferon or antiviral agents. The most frequently 
used antiviral agents against hepatitis B virus (HBV) are entecavir (1), tenofovir, adefovir, telbivudine, 
and lamivudine (Figure 1).2  
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Figure 1. Antiviral agents used against HBV. 
Of these, entecavir is considered one of the best choices for the treatment of chronic patients due to its 
lack of significant adverse effects and the low risk of inducing long-term resistance to the drug.3  
Entecavir (BMS-200475), first synthesized by Bristol-Myers Squibb,4 was identified as a potent 
inhibitor of HBV in vitro (ED50 = 3 nM)5 and was later commercialized as Baraclude®. Its patent is due 
to expire in 2015 in the US and soon afterwards in other countries. In anticipation of the availability of a 
generic version, a plethora of patent applications has appeared recently.6,8a-b Most the reported synthetic 
approaches for the stereoselective construction of the cyclopentane framework are based on 
transformation of a cyclopentane moiety,6,7 and only a few start with an acyclic precursor that is 
subsequently cyclized.8 In this paper we disclose a concise synthesis of 1 from acyclic precursors.9 As 
shown in Scheme 1, the retrosynthetic analysis of this carbocyclic nucleoside10 takes advantage of the 
ability of epoxides to act as effective precursors of radicals. The key step involves the Ti(III)-mediated 
generation of a β-alkoxy carbon radical11 from epoxide 4 that can cyclize to a methylene cyclopentane 5 
through the cyclic transition state shown in Figure 2. 
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Figure 2. Proposed TS for the radicalary cyclization of 4. 
It is worth noting that the proposed radical cyclization has been reported previously in a failed attempt 
to prepare 1. Thus, Ziegler12 prepared epoxide 4b (PG1=PG2=TBS) from protected D-glucose in 9 steps 
and reported very good cyclization yields when 4b was treated with 3 equiv of Cp2TiCl2 in the presence 
of an excess of Zn in THF. Considering these precedents, we implemented an alternative route to 
epoxides 4 where the key step is an enantioselective acetate aldol addition13 of methyl ketone 2 to 
acrolein followed by the in situ reduction of the corresponding β-hydroxy ketone. This approach 
drastically reduces the number of steps involved and potentially provides more flexibility with respect to 
the election of protecting groups (PG1 and PG2).  
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Results and Discussion 
The enantioselective aldol reaction of 4-trimethylsilyl-3-butyn-2-one (2) with acrolein was carried out 
using (+)-chlorodiisopinocampheylborane ((+)-DIPCl) as source of chirality.14 As shown in Scheme 2, 
the in situ reduction of the resulting chelate15 with LiBH4 followed by an oxidative work up provided 3a 
(PG1=PG2=H) as a mixture of diols in 66% yield and moderate selectivity (80:20 er, 90:10 syn/anti 
ratio) after chromatography. It is worth noting that recrystallization from hexanes afforded pure syn diol 
3a (98% er, >99% dr) in 37% overall yield. Despite the low yield, this method is very straightforward 
and allows the skeleton of the cyclization precursor 4 to be constructed from easily available 
commercial starting materials in a one-pot procedure. 
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Scheme 2 
Conversion of 3a into the Ziegler’s epoxide 4b or its TMS-derivative 6 is very efficient (Scheme 3). 
Unfortunately, the cyclization of 4b leads to the methylene cyclopentane 5b (PG1=PG2=TBS, PG3=H, 
Scheme 1) where the differentiation of TBS ethers would be problematic during the introduction of the 
nucleobase. On the other hand, our preliminary attempts at the cyclization of epoxide 6 led to the 
complete degradation of the starting material. With a view to circumventing these limitations we 
evaluated the cyclization reactions for a series of epoxides of type 4 with different protecting groups 
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(Scheme 1, PG1≠PG2). 
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CH2Cl2, 15 h, rt, 95%; (c) m-CPBA, CH2Cl2, 15 h, rt, 4b: 
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CH2Cl2, 15 h, rt, 6: 91%.
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Scheme 3 
Preparation of 4 (PG1≠PG2) from 3a or 7a is not trivial in some cases because there is no reliable 
information in the literature on the selective monoprotection of secondary propargylic alcohols in the 
presence of secondary allylic ones. In order to establish the viability of the monoprotection reactions, a 
set of silylations and benzoylations were carried out on these diols. Table 1 summarizes the optimized 
conditions found for each substrate and highlights the fact that protection of the propargylic position is 
clearly favored over the protection of the corresponding allylic position. Moderate-to-good yields of the 
desired monoprotected diol can be achieved while at the same time maintaining the yields of diprotected 
byproducts below 15%. Yields of the monoprotected allylic alcohol are less than 5%. 
TABLE 1. Monoprotection of diols 3a and 7a. 
3a (R = TMS)
7a (R = H)
R'O OH
R
R'Cl (1.2 equiv)
Base, rt  
Entry Diol R R’ Base Solvent t (h) Yield (product) 
1a 3a TMS TBS Imidazole THF 5 65% (3c) 
2 3a TMS TBDPS  Imidazole THF 5 62% (3d) 
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3 3a TMS TIPS  Imidazole THF 15 69% (3e) 
5a 7a H TBS  Imidazole CH2Cl2 5 54% (7c) 
6a 7a H Bz  DIPEA CH2Cl2 15 86% (7f) 
  a R’Cl (1.1 equiv) was added. 
Based on these results, we attempted to prepare the diprotected epoxides 4g-j (Scheme 4) through 
selective monoprotection of 3a followed by the removal of the TMS group to afford 7c-e monoalcohols. 
The sequence was completed by epoxidation with m-CPBA and final protection of the remaining 
alcohol. The alternative pathway, in which the epoxidation was the final step was less convenient since 
the epoxidation of protected allylic alcohols is slow and it is even slower with acetylated allylic 
alcohols. On the other hand, for the preparation of 4k via 7f removal of the TMS group of 3a to afford 
diol 7a was the first step in the sequence since this deprotection was not compatible with a benzoate 
group.  
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(a) 3c, 3d or 3e, K2CO3 (0.25-0.5 equiv), MeOH, 1-3 h, rt, 7c: 99%, 
7d: 84%,7e: 95%; (b) 7c-f, m-CPBA (2.5-6.0 equiv), CH2Cl2, 2.5-15 h, 
rt, 4c: 97%, 4d: 99%, 4e: 95%,  4f: 87%; (c) 4c or 4e, Ac 2O (1.2 
equiv), NEt3, CH2Cl2, 1 h, rt, 4g: 98%, 4j: 90%; (d) 4c,TBDPSCl (2.0 
equiv), imidazole, THF, rt, 48 h, 4h: 79%; (e) 4d or 4f,TBSCl (1.9-2.6 
equiv), imidazole, THF, rt, 24 h, 4i: 71%, 4k: 67%.
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4c, R = TBS
4d, R = TBDPS
4e, R = TIPS
4f, R = Bz
4g, R = TBS, R' = Ac
4h, R = TBS, R' = TBDPS
4i, R = TBDPS, R' = TBS
4j, R = TIPS, R' = Ac
4k, R = Bz, R' = TBS
 
Scheme 4 
With epoxides 4g-k in hand, we attempted to bring about their Ti(III)-mediated cyclization by treatment 
with Cp2TiCl2 in the presence of an excess of a metal M such as Zn or Mn (Scheme 5). In this type of 
reaction the metal reduces Cp2TiCl2 to a Cp2TiCl· radical (8). Reaction of 8 with the corresponding 
epoxide 4 generates the titanocene(IV) β-alkoxy carbon radical 9 that gives rise to a cyclic vinyl radical 
10. This radical can then be quenched either by a hydrogen donor or by another Ti(III) radical to afford 
11 or 12 (X=H or Cp2TiCl, respectively). Protonolysis of 11/12 should give methylene cyclopentane 5. 
Although this reaction can be catalytic in Cp2TiCl2, Ziegler12 described the cyclization of epoxide 4b 
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using an excess of Cp2TiCl2. Under these conditions, however, we could not reproduce the reported 
yield. When epoxide 4b was treated with Cp2TiCl2 in the presence of an excess of Zn following the 
described procedure, the methylene cyclopropane 5b (PG1=PG2=TBS, PG3=H) was obtained with good 
diastereoselectivity but in a yield of only 30%. 
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Scheme 5 
Fortunately, yields could be increased to 50% by replacing the aqueous H2SO4 work-up with a treatment 
with saturated NH4Cl (entry 1, Table 2). Under these optimized conditions cyclizations of epoxides 4g-k 
were carried out. The results are summarized in Table 2 and it can be seen that the election of the 
propargylic alcohol protecting group (R) is critical. TBS provided the best yields (entries 1, 2, and 5) 
when compared with TIPS and TBDPS (entries 3 and 6) and better selectivity than the benzoyl group 
(entry 4). In sharp contrast, protection of the allylic alcohol has little effect on yield or selectivity 
(entries 1, 2, and 5). These results suggested 4b, 4g and 4h to be the most promising candidates for 
cyclization. We finally chose the transformation of 4g to 5g as the key step of the synthesis because it 
provided better overall yield from diol 3a and allowed differentiation of the protected alcohols.  
TABLE 2. Stoichiometric cyclization of propargylic epoxides 4b and 4g-k. 
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4b-k 5b-k
Cp2TiCl2 (3 equiv)
Zn (10.5 equiv)
THF, 15 h, rt
O
RO OR'
HO OR
R'O  
Entry Epoxide R R’ Product Yield (%) dra 
1 4b TBS TBS 5b 50 95:5 
2 4h TBS TBDPS 5h 43 >97:3 
3 4i TBDPS TBS 5i <10a n. d. 
4 4k Bz TBS 5k 49 90:10 
5 4g TBS Ac 5g 40 96:4 
6 4j TIPS Ac 5j 0 - 
a Not chromatographically isolated. Yield estimated from 1H-NMR. 
The Ti-catalytic version of the cyclization was also explored in an attempt to improve the process. In the 
stoichiometric process 11/12 are cleaved in the final step by treatment with saturated NH4Cl. In the 
catalytic version an alternative proton source is required to cleave 11/12 and regenerate the catalyst. 
Gansäuer16 described the use of collidine hydrochloride as the most convenient reagent for doing so. 
After careful optimization of the reaction conditions we were able to carry out the cyclization of 4g to 
5g using 20% catalyst and collidine hydrochloride as proton source with excellent selectivity and 
comparable yields to the stoichiometric version (Table 3, entries 1 and 4). Mn provides similar yields to 
Zn but requires less metal to generate 8. 
On the other hand, we found that the use of trimethylsilylcollidinium chloride17 instead of collidine 
hydrochloride (entries 2 and 5) while not improving yields did improve the reproducibility of the 
process at larger scales. A further improvement was achieved by introducing Vaska’s complex, 
IrCl(CO)(PPh3)2 in the presence of H2 as hydrogen donor18 (entries 3, 6, and 7). 
TABLE 3. Catalytic cyclization of 4g to cyclopentane 5g. 
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4g 5g
Cp2TiCl2 (20% mol)
Collidine·HCl (3 equiv) or 
collidine (8 equiv) / TMSCl (4 equiv)
IrCl(CO)(PPh3)2 / H2 (4 bar)
THF, 4 h, rt
Zn (3 equiv) or Mn (2 equiv)
 
Entry M Collidinium Salt IrCl(CO)(PPh3)2 Yield (%) 
1 Zn  Collidine·HCl  - 36 
2 Zn  Collidine/TMSCl - 38 
3 Zn Collidine/TMSCl 5 % 51 
4 Mn  Collidine·HCl - 42 
5 Mn  Collidine/TMSCl - 36 
6 Mn Collidine/TMSCl 5 % 49 
7 Mn Collidine/TMSCl 10 % 58 
 
The last step in the preparation of the carbocyclic moiety of Entecavir was the protection of the 
primary hydroxyl group of 5g in the form of a p-nitrobenzoyl ester 5l. The election of this protecting 
group is important because 5l can be crystallized and purified. By this means chromatographic 
purifications of intermediates 3a to 5g (which are oils) can be avoided (Scheme 6).  
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(a) TBSCl (1.1 equiv), imidazole, THF, 6 h, rt, 69%; (b) 
K2CO3 cat., MeOH, 1 h, rt, 95%; (c) m-CPBA, CH2Cl2, 
15 h, rt, 95%; (d) Ac2O, NEt3, DMAP cat., CH2Cl2, 1 h, 
rt, 95%; (e) Cp 2TiCl2 20% mol., IrCl(CO)(PPh 3)2 10% 
mol., Mn (2 equiv), collidine, TMSCl, H2 (4 bar), THF, 4 
h, rt, 58%; (f) p-O2NBzCl, NEt3, CH2Cl2, 1.5 h, rt, 74%. 
(g) 5%  (+)-CSA,  MeOH, 3 h, rt, 89%. (h) 2-amino-6-
chloropurine, DIAD,  PPh3, THF, 3 h,  -10 º C, 61%. (i) 
HCOOH, 50 º C, 9h, 92%. (j) MeONa, MeOH, 1 h, rt, 
72%.
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Scheme 6 
Final conversion of 5l to pharmaceutical-grade Entecavir was straightforward. Selective acidic 
deprotection of the TBS ether followed by Mitsunobu reaction with 2-amino-6-chloropurine6x led to the 
chloroderivative 13 that was transformed into protected Entecavir 14 by treatment with formic acid. 
Saponification of 14 then gave Entecavir of pharmaceutical grade. Reversal of the order of the last two 
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steps decreased the overall yield and increased the formation of impurities that impeded the 
crystallization of the final product as did the direct acid hydrolysis of both of the esters and the 
chloropurine moiety. 
Conclusions 
 A straightforward synthesis of Entecavir was achieved in 11 steps from commercially available 
starting materials. The cyclopentane skeleton was prepared from acyclic precursors by a boron-aldol 
reaction and a Ti(III)-catalyzed cyclization of an epoxide to an alkyne as key steps. The carbocylic 
structure obtained in this way was attached to a purine moiety by a Mitsunobu reaction. It is worth 
mentioning that the use of the p-nitrobenzoyl group in the final steps allows purification by 
crystallization thus avoiding chromatography and making the synthesis amenable to scale-up. The 
selective hydrolysis of the 6-chloropurine unit with formic acid is also essential in order to facilitate the 
crystallization of the final product. 
Experimental Section 
All reactions involving moisture- or air-sensitive reagents were performed in oven-dried glassware 
under N2. Chemical shifts (δ) were quoted in parts per million and referenced for 1H NMR to internal 
TMS (for CDCl3) or residual solvent peak δ 2.50 ppm (for DMSO-d6). 13C NMR was referenced to 
CDCl3 (δ 77.0 ppm) or DMSO-d6 (δ 39.5 ppm). Column chromatography was performed on silica gel 
(Merck 230-400 mesh). HRMS analyses were recorded on a LC/MSD-TOF mass spectrometer. 
(3S,5R)-7-(Trimethylsilyl)hept-1-en-6-yne-3,5-diol (3a). NEt3 (11.60 mL, 85 mmol) was added to a 
stirred solution of (+)–DIPCl (90-105%) (25.000 g, 78 mmol) in anhydrous THF (40 mL) under N2 at 0 
ºC. 4-Trimethylsilyl-3-butyn-2-one (98%, 9.78 g, 70 mmol) was added dropwise and the mixture was 
stirred for 2 h at -5 ºC–0 ºC. The solution was cooled to -78 ºC and a solution of acrolein (90%, 7.62 
mL, 103 mmol) in anhydrous THF (20 mL) was added slowly and the mixture was stirred for 1 h at -78 
ºC. A 2 M solution of LiBH4 in hexanes (53 mL, 106 mmol) was added slowly and the mixture was 
stirred for a further 1 h at -78 ºC. After careful quenching with saturated NH4Cl (40 mL) at -78 ºC the 
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mixture was allowed to warm to rt over 30 min. After partitioning between H2O (40 mL) and MTBE (90 
mL) the aqueous layer was extracted with MTBE (25 mL). The organic phases were combined and 
dried (MgSO4). Solvent removal afforded a pale yellow oil (62 g). THF:H2O (3:1, 80 mL) was added 
under N2 at rt followed by NaOAc (4.40 g, 54 mmol) and the mixture was cooled to 0 ºC. H2O2 (30%, 
30 mL, 5 equiv) was added dropwise over 10 min and the mixture was stirred for a further 10 min at 0 
ºC and 30 min at rt. After cooling to 0 ºC a saturated solution of Na2S2O3 (30 mL) was added slowly and 
the mixture was stirred for 10 min at 0 ºC and 15 min at rt. H2O (20 mL) and MTBE (35 mL) were 
added and the organic phase was decanted. The aqueous layer was extracted with MTBE (10 mL) and 
the combined organic extracts were dried (MgSO4). Solvent removal gave a clear oil (49.2 g) that was 
purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 60:40 (gradient elution)] to 
give 9.130 g of a mixture of diols (er 80:20; syn/anti 90:10). 
Recrystallization from hexanes afforded the product as a white crystalline solid (3a,9a 5.2 g, 37% 
overall yield, er 98%). Mp 80–82 ºC. [α]D25 +2.3 (c 1.0, CHCl3). IR (film): 3349, 2956, 2922, 2899, 
2176 cm-1. 1H NMR (CDCl3, 400 MHz): δ 5.90 (ddd, J = 17.2, 10.4, 5.9 Hz, 1H), 5.29 (ddd, J = 17.2, 
1.4, 1.3 Hz, 1H), 5.14 (ddd, J = 10.4, 1.4, 1.3 Hz, 1H), 4.64 (dd, J = 7.9, 5.2 Hz, 1H), 4.43-4.37 (m, 
1H), 2.80 (bs, 1H), 2.46 (bs, 1H), 2.03-1.89 (m, 2H), 0.18 (s, 9H). 13C NMR (CDCl3, 101 MHz): δ 
140.1, 115.1, 106.1, 89.9, 72.1, 62.0, 44.0, –0.1. HRMS (ESI): m/z calcd. for C10H18O2SiNa+ [M+Na]+ 
221.0969; found 221.0974. 
(3S,5R)-3,5-Bis(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yne (3b). A solution of 
TBSCl (0.800 g, 5.30 mmol) in anhydrous CH2Cl2 (5 mL) was added dropwise to a solution of diol 3a 
(0.500 g, 2.52 mmol) and imidazole (0.377 g, 5.54 mmol) in anhydrous CH2Cl2 (5 mL) at 0 ºC under N2. 
The mixture was allowed to warm to rt and was stirred for 15 h. A 22% solution of NH4Cl (5 mL) was 
added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the aqueous 
phase was extracted with CH2Cl2 (5 mL). The organic phase was dried (MgSO4) and the solvent was 
removed affording an oil that was purified by flash chromatography (silica gel, hexanes-AcOEt 95:5) to 
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give 1.030 g (96%) of the title compound9a (3b) as a yellow oil. [α]D25 +21.6 (c 1.0, CHCl3). IR (film): 
3071, 2952, 2930, 2897, 2858, 2172 cm-1. 1H NMR (CDCl3, 300 MHz): δ 5.81 (ddd, J = 17.2, 10.3, 6.4 
Hz, 1H), 5.15 (dt, J = 17.2, 1.4 Hz, 1H), 5.04 (dt, J = 10.3, 1.4 Hz, 1H), 4.46 (dd, J = 7.7, 6.4 Hz, 1H), 
4.33-4.24 (m, 1H), 1.90 (ddd, J = 13.2, 8.1, 6.7 Hz, 1H), 1.74 (ddd, J = 13.2, 7.7, 5.2 Hz, 1H), 0.90 (s, 
9H), 0.89 (s, 9H), 0.16 (s, 9H), 0.13 (s, 3H), 0.10 (s, 3H), 0.07 (s, 3H), 0.03 (s, 3H). 13C NMR (CDCl3, 
101 MHz): δ 141.3, 114.4, 107.4, 89.5, 71.3, 61.3, 46.9, 26.0, 25.9, 18.4, 18.3, 0.0, -4.1, -4.3, -4.8, -4.8. 
HRMS (ESI): m/z calcd. for C22H47O2Si3+ [M+H]+ 427.2878; found 427.2867. 
(3S,5R)-5-(tert-Butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3c). A solution of 
TBSCl (4.180 g, 27.73 mmol) in anhydrous THF (20 mL) was added dropwise to a solution of diol 3a 
(5.000 g, 25.21 mmol) and imidazole (2.060 g, 30.25 mmol) in anhydrous THF (60 mL) at 0 ºC under 
N2, and the mixture was allowed to warm to rt and was stirred for 5 h. A 22% solution of NH4Cl (25 
mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the 
organic phase was dried (MgSO4) and the solvent was removed affording an oil that was purified by 
flash chromatography [silica gel, hexanes-AcOEt, from 97:3 to 80:20 (gradient elution)] to give 5.123 g 
(65%) of the title compound9a (3c) as a pale yellow oil. [α]D25 +39.9 (c 1.0, CHCl3). IR (film): 3424, 
3081, 2958, 2930, 2898, 2858, 2172 cm-1. 1H NMR (CDCl3, 300 MHz): δ 5.86 (ddd, J = 17.2, 10.5, 5.6 
Hz, 1H), 5.28 (dt, J = 17.2, 1.5 Hz, 1H), 5.11 (dt, J = 10.5, 1.5 Hz, 1H), 4.59 (dd, J = 7.9, 5.3 Hz, 1H), 
4.42-4.30 (m, 1H), 2.98 (d, J = 2.4 Hz, 1H), 1.99-1.86 (m, 2H), 0.91 (s, 9H), 0.19 (s, 3H), 0.16 (s, 12H). 
13C NMR (CDCl3, 101 MHz): δ 140.3, 114.6, 106.7, 90.3, 71.5, 62.9, 45.1, 25.9, 18.2, –0.2, –4.1, –4.8. 
HRMS (ESI): m/z calcd. for C16H33O2Si2+ [M+H]+ 313.2014; found 313.2005. 
(3S,5R)-5-(tert-Butyldiphenylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3d). TBDPSCl (1.57 
mL, 6.10 mmol) was added dropwise to a solution of diol 3a (1.000 g, 5.04 mmol) and imidazole (0.481 
g, 7.06 mmol) in anhydrous THF (9.5 mL) at 0 ºC under N2, and the mixture was allowed to warm to rt 
and was stirred for 5 h. A 22% solution of NH4Cl (5 mL) was added slowly and the mixture was stirred 
for 10 min. The mixture was partitioned and the organic phase was dried (MgSO4), and the solvent was 
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removed affording an oil that was purified by flash chromatography [silica gel, hexanes-AcOEt, from 
95:5 to 90:10 (gradient elution)] to give 1.363 g (62%) of the title compound (3d) as a pale yellow oil. 
[α]D25 +62.5 (c 1.0, CHCl3). IR (film): 3446, 3071, 2958, 2931, 2894, 2857 cm-1. 1H NMR (CDCl3, 400 
MHz): δ 7.77-7.66 (m, 4H), 7.45-7.33 (m, 6H), 5.84 (ddd, J = 17.2, 10.5, 5.6 Hz, 1H), 5.23 (dt, J = 
17.2, 1.5 Hz, 1H), 5.07 (dt, J = 10.5, 1.5 Hz, 1H), 4.54 (t, J = 6.3 Hz, 1H), 4.51-4.43 (m, 1H), 2.64 (d, J 
= 3.4 Hz, 1H), 2.01-1.85 (m, 2H), 1.06 (s, 9H), 0.10 (s, 9H). 13C NMR (CDCl3, 101 MHz): δ 140.4, 
136.2, 136.0, 134.9, 133.6, 133.3, 130.0, 129.8, 129.7, 127.8, 127.7, 127.5, 114.5, 106.2, 91.3, 70.6, 
62.8, 45.2, 27.0, 26.7, 19.4, -0.4. HRMS (ESI): m/z calcd. for C26H37O2Si2+ [M+H]+ 437.2327; found 
437.2325. 
(3S,5R)-5-(Triisopropylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3e). TIPSCl (5.20 mL, 
30.25 mmol) was added dropwise to a solution of diol 3a (5.000 g, 25.21 mmol) and imidazole (2.230 g, 
32.77 mmol) in anhydrous THF (40 mL) at 0 ºC under N2, and the mixture was allowed to warm to rt 
and was stirred for 15 h. A 22% solution of NH4Cl (20 mL) was added slowly and the mixture was 
stirred for 10 min. The mixture was partitioned and the organic phase was extracted with MTBE (2 × 20 
mL). The combined organic phases were dried (MgSO4), and the solvent was removed affording an oil 
that was purified by flash chromatography [silica gel, hexanes-AcOEt, from 97:3 to 80:20 (gradient 
elution)] to give 6.173 g (69%) of the title compound as a pale yellow oil. [α]D25 +23.5 (c 0.6, CHCl3). 
IR (film): 3421, 3074, 2944, 2894, 2867, 2167 cm-1. 1H NMR (CDCl3, 300 MHz): δ 5.89 (ddd, J = 17.2, 
10.5, 5.6 Hz, 1H), 5.28 (dt, J = 17.2, 1.5 Hz, 1H), 5.11 (dt, J = 10.5, 1.5 Hz, 1H), 4.71 (t, J = 6.4 Hz, 
1H), 4.49-4.41 (m, 1H), 2.92 (d, J = 2.7 Hz, 1H), 1.95-1.89 (m, 2H), 1.27-1.13 (m, 3H), 1.13-1.04 (m, 
18H). 13C NMR (CDCl3, 101 MHz): δ 140.5, 114.4, 106.9, 90.3, 71.1, 62.5, 45.5, 18.2, 17.9, 12.5, -0.2. 
HRMS (ESI): m/z calcd. for C19H39O2Si2+ [M+H]+ 355.2483; found 355.2478. 
(3S,5R)-Hept-1-en-6-yne-3,5-diol (7a). K2CO3 (0.348 g, 2.52 mmol) was added in one portion to a 
stirred solution of 3a (1.000 g, 5.04 mmol) in anhydrous MeOH (10 mL) at rt under N2. The mixture 
was then stirred for 1 h. A buffer solution (pH=7, 10 mL) and CH2Cl2 (10 mL) were added, the mixture 
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was partitioned and the organic phase was dried (MgSO4). Solvent removal gave the title compound 
(7a)12 as a yellow oil 0.628 g (98%). [α]D25 +5.8 (c 1.0, CHCl3). IR (film): 3347, 3290, 3060, 2983, 
2953, 2922, 2887, 2113 cm-1. 1H NMR (CDCl3, 400 MHz): δ 5.86 (ddd, J = 17.2, 10.4, 6.0 Hz, 1H), 
5.26 (dt, J = 17.2, 1.4 Hz, 1H), 5.11 (dt, J = 10.4, 1.4 Hz, 1H), 4.61 (ddd, J = 8.3, 5.1, 2.1 Hz, 1H), 4.41-
4.34 (m, 1H), 2.75 (bs, 1H), 2.49 (d, J = 2.1 Hz, 1H), 2.35 (bs, 1H), 2.03-1.84 (m, 2H). 13C NMR 
(CDCl3, 101 MHz): δ 140.1, 115.2, 84.5, 73.3, 72.0, 61.3, 43.9. HRMS (ESI): m/z calcd. for 
C7H10NaO2+ [M+Na]+ 149.0573; found 149.0572. 
(3S,5R)-3,5-Bis(tert-butyldimethylsilyloxy)hept-1-en-6-yne (7b). A solution of TBSCl (2.059 g, 
13.60 mmol) in anhydrous CH2Cl2 (5 mL) was added dropwise to a solution of diol 7a (0.820 g, 6.50 
mmol) and imidazole (1.062 g, 15.60 mmol) in anhydrous CH2Cl2 (3 mL) at 0 ºC under N2, and the 
mixture was allowed to warm to rt and was stirred for 15 h. A 22% solution of NH4Cl (5 mL) was added 
slowly and the mixture was stirred for 10 min. The mixture was partitioned and the aqueous phase was 
extracted with CH2Cl2 (2 × 10 mL). The combined organic phases were dried (MgSO4) and the solvent 
was removed affording an oil that was purified by flash chromatography [silica gel, hexanes-AcOEt, 
from 97:3 to 80:20 (gradient elution)] to give 2.280 g (95%) of the title compound (7b)12 as a pale 
yellow oil. [α]D25 +13.0 (c 1.0, CHCl3). IR (film): 3306, 3093, 2958, 2930, 2887, 2858 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ 5.81 (ddd, J = 17.2, 10.4, 6.5 Hz, 1H), 5.17 (dt, J = 17.2, 1.2 Hz, 1H), 5.05 (dt, J 
= 10.4, 1.2 Hz, 1H), 4.47 (ddd, J = 8.2, 6.5, 2.0 Hz, 1H), 4.33-4.26 (m, 1H), 2.42 (d, J = 2.0 Hz, 1H), 
1.99-1.74 (m, 2H), 0.91 (s, 9H), 0.90 (s, 9H), 0.14 (s, 3H), 0.11 (s, 3H), 0.07 (s, 3H), 0.03 (s, 3H). 13C 
NMR (CDCl3, 101 MHz): δ 141.3, 114.4, 85.4, 72.9, 71.1, 60.6, 47.2, 26.0, 25.9, 18.4, 18.3, -4.1, -4.4, -
4.8, -4.9. HRMS (ESI): m/z calcd. for C19H39O2Si2+ [M+H]+ 355.2483; found 355.2486. 
(3S,5R)-5-(tert-Butyldimethylsilyloxy)hept-1-en-6-yn-3-ol (7c). K2CO3 (0.101 g, 0.73 mmol) was 
added in one portion to a stirred solution of 3c (0.455 g, 1.46 mmol) in anhydrous MeOH (4.5 mL) at rt 
under N2 and the mixture was stirred for 1 h. After solvent removal CH2Cl2 (10 mL) was added to the 
residue and the solution was filtered and dried (MgSO4). Solvent removal gave the title compound (7c)9a 
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as a pale yellow oil (0.366 g, 99%). [α]D25 +32.7 (c 1.0, CHCl3). IR (film): 3417, 3311, 3079, 2956, 
2930, 2886, 2858, 2109 cm-1. (CDCl3, 300 MHz): δ 5.88 (ddd, J = 17.2, 10.4, 5.7 Hz, 1H), 5.29 (dt, J = 
17.2, 1.5 Hz, 1H), 5.12 (dt, J = 10.4, 1.5 Hz, 1H), 4.61 (ddd, J = 7.8, 5.8, 2.1 Hz, 1H), 4.42-4.33 (m, 
1H), 2.71 (d, J = 2.7 Hz, 1H), 2.47 (d, J = 2.1 Hz, 1H), 2.03-1.85 (m, 2H), 0.92 (s, 9H), 0.19 (s, 3H), 
0.16 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 140.3, 114.8, 84.9, 73.5, 71.2, 62.0, 45.2, 25.9, 18.2, -4.2, -
4.9. HRMS (ESI): m/z calcd. for C13H24NaO2Si+ [M+Na]+ 263.1438; found 263.1431. 
(3S,5R)-5-(tert-Butyldiphenylsilyloxy)hept-1-en-6-yn-3-ol (7d). K2CO3 (0.080 g, 0.57 mmol) was 
added in one portion to a stirred solution of 3d (0.500 g, 1.14 mmol) in anhydrous MeOH (5 mL) at rt 
under N2 and the mixture was stirred for 3 h. A buffer solution (pH=7, 5 mL) and MTBE (15 mL) were 
added, the mixture was partitioned and the organic phase was dried (MgSO4). Solvent removal gave the 
title compound (7d) as a pale yellow oil (0.350 g, 84%). [α]D25 +34.3 (c 1.0, CHCl3). IR (film): 3453, 
3303, 3071, 2956, 2930, 2891, 2858 cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.78-7.69 (m, 4H), 7.47-7.36 
(m, 6H), 5.88-5.78 (m, 1H), 5.22 (dt, J = 17.2, 1.4 Hz, 1H), 5.08 (dt, J = 10.5, 1.4 Hz, 1H), 4.60 (td, J = 
6.5, 2.1 Hz, 1H), 4.47-4.39 (m, 1H), 2.35 (d, J = 2.1 Hz, 1H), 2.15 (m, 1H), 1.96-1.90 (m, 2H), 1.10 (s, 
9H). 13C NMR (CDCl3, 101 MHz): δ 140.5, 136.2, 136.0, 133.3, 133.3, 130.4, 129.9, 127.8, 127.6, 
114.6, 84.5, 74.2, 70.3, 62.1, 45.3, 27.0, 19.4. HRMS (ESI): m/z calcd. for C23H28NaO2Si+ [M+Na]+ 
387.1751; found 387.1752. 
(3S,5R)-5-(Triisopropylsilyloxy)hept-1-en-6-yn-3-ol (7e). K2CO3 (0.526 g, 3.81 mmol) was added in 
one portion to a stirred solution of 3e (6.000 g, 15.23 mmol) in anhydrous MeOH (50 mL) at rt under N2 
and the mixture was stirred for 1 h. A buffer solution (pH=7, 15 mL) and MTBE (15 mL) were added, 
the mixture was partitioned and the organic phase was dried (MgSO4). Solvent removal gave the title 
compound (7e) as a pale yellow oil (4.084 g, 95%). [α]D25 +15.7 (c 1.0, CHCl3). IR (film): 3421, 3311, 
3083, 2944, 2893, 2867 cm-1. 1H NMR (CDCl3, 300 MHz): δ 5.97-5.83 (m, 1H), 5.29 (ddd, J = 17.3, 
2.7, 1.4 Hz, 1H), 5.12 (ddd, J = 10.4, 2.6, 1.4 Hz, 1H), 4.74 (td, J = 6.7, 2.1 Hz, 1H), 4.50-4.39 (m, 1H), 
2.55 (d, J = 3.0 Hz, 1H), 2.49-2.46 (m, 1H), 1.99-1.91 (m, 2H), 1.24-1.06 (m, 21H). 13C NMR (CDCl3, 
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101 MHz): δ 140.5, 114.6, 85.0, 73.6, 70.9, 61.8, 45.5, 18.2, 18.1, 17.8, 12.4. HRMS (ESI): m/z calcd. 
for C16H31O2Si+ [M+H]+ 283.2088; found 283.2077. 
(3R,5S)-5-Hydroxyhept-6-en-1-yn-3-yl benzoate (7f). i-Pr2NEt (0.76 mL, 4.37 mmol) was added 
dropwise to a solution of 7a (0.460 g, 3.64 mmol) in anhydrous CH2Cl2 (9 mL) at 0 ºC under N2. BzCl 
(0.46 mL, 3.96 mmol) was added dropwise at 0 ºC and the mixture was warmed to rt and stirred for 15 
h. MeOH (2 mL) was added and the mixture was stirred for 10 min. After solvent removal the resulting 
oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 80:20 
(gradient elution)] to give the title compound (7f, as the major isomer in a 91:9 mixture of 
monobenzoylated regioisomers) as a pale yellow oil (0.741 g, 86%). [α]D25 +26.0 (c 1.0, CHCl3). IR 
(film): 3467, 3294, 3071, 2959, 2928, 2885, 2121, 1719 cm-1. 1H NMR (CDCl3, 400 MHz): δ 8.11-8.03 
(m, 2H), 7.63-7.54 (m, 1H), 7.50-7.41 (m, 2H), 5.93 (ddd, J = 17.1, 10.4, 6.0 Hz, 1H), 5.79 (ddd, J = 
7.6, 6.5, 2.2 Hz, 1H), 5.30 (dt, J = 17.1, 1.2 Hz, 1H), 5.17 (dt, J = 10.4, 1.2 Hz, 1H), 4.53-4.42 (m, 1H), 
2.56 (d, J = 2.2 Hz, 1H), 2.30-2.05 (m, 2H). 13C NMR (CDCl3, 101 MHz): δ 165.4, 140.0, 133.4, 129.9, 
129.8, 128.5, 115.5, 81.0, 74.7, 69.9, 62.2, 41.7. HRMS (ESI): m/z calcd. for C14H14NaO3+ [M+Na]+ 
253.0835; found 253.0837. 
(1S,3R)-1,3-Bis(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)-5-(trimethylsilyl)pent-4-yne (6). A 
solution of 3b (0.900 g, 2.11 mmol) in anhydrous CH2Cl2 (5 mL) was added to a suspension of m-CPBA 
(77%, 1.417 g, 6.32 mmol) in anhydrous CH2Cl2 (10 mL) at rt under N2 and the mixture was stirred at rt 
for 15 h. The mixture was filtered and the organic phase was washed with saturated Na2S2O3 (5 mL), 
saturated NaHCO3 (10 mL), dried (MgSO4) and the solvent was removed to give the title compound (6) 
as a yellow oil (0.853 g, 91%). IR (film): 3048, 2956, 2929, 2887, 2857 cm-1. 1H NMR (CDCl3, 400 
MHz): δ 4.61-4.54 (m, 1H), 3.88 (ddd, J = 6.5, 6.4, 4.2 Hz, 0.4H), 3.49 (ddd, J = 8.7, 7.0, 4.5 Hz, 
0.6H), 3.00-2.92 (m, 1H), 2.83-2.76 (m, 0.6H), 2.70-2.64 (m, 0.8H), 2.56 (dd, J = 4.9, 2.7 Hz, 0.6H), 
2.02-1.80 (m, 2H), 0.92-0.90 (m, 18H), 0.16-0.08 (m, 21H). 13C NMR (CDCl3, 101 MHz): δ 106.8, 
106.7, 90.1, 90.0, 72.7, 68.4, 61.2, 61.1, 56.0, 54.8, 45.2, 44.3, 43.7, 43.2, 26.0, 25.9, 18.4, 18.3, 0.0, 
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0.1, -4.2, -4.4, -4.5, -4.8, -4.9, -5.1. HRMS (ESI): m/z calcd. for C22H47O3Si3+ [M+H]+ 443.2828; found 
443.2827. 
(1S,3R)-1,3-Bis(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yne (4b). A solution of 7b (2.260 
g, 6.37 mmol) in anhydrous CH2Cl2 (5 mL) was added to a suspension of m-CPBA (77%, 3.180 g, 19.12 
mmol) in anhydrous CH2Cl2 (25 mL) at rt under N2 and the mixture was stirred at rt for 15 h. The 
mixture was filtered and the organic phase was washed with saturated Na2S2O3 (10 mL), saturated 
NaHCO3 (2 × 10 mL), dried (MgSO4) and the solvent was removed to give an oily residue that was 
purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 50:50 (gradient elution)] to 
give the title compound (4b)12 as a pale yellow oil (2.240 g, 95%). IR (film): 3311, 3045, 2954, 2928, 
2886, 2857 cm-1. 1H NMR (CDCl3, 300 MHz): δ 4.58 (m, 1H), 3.83 (dd, J = 7.8, 4.7 Hz, 0.4H), 3.49 
(ddd, J = 8.7, 6.9, 4.3 Hz, 0.6H), 2.97 (ddd, J = 6.9, 4.1, 2.7 Hz, 0.6H), 2.93 (ddd, J = 4.5, 3.9, 2.7 Hz, 
0.4H), 2.79 (dd, J = 4.8, 4.2 Hz, 0.6H), 2.72-2.64 (m, 0.8H), 2.57 (dd, J = 4.9, 2.7 Hz, 0.6H), 2.43 (d, J 
= 2.1 Hz, 0.4H), 2.41 (d, J = 2.1 Hz, 0.6H), 2.06-1.79 (m, 2H), 0.92-0.88 (m, 18H), 0.16-0.06 (m, 12H). 
13C NMR (CDCl3, 101 MHz): δ 85.0, 84.9, 73.3, 73.3, 72.4, 68.6, 60.5, 56.0, 54.7, 45.1, 44.7, 44.1, 
43.5, 26.1, 26.0, 25.9, 18.4, 18.3, 18.2, -4.2, -4.5, -4.9, -5.0, -5.1. HRMS (ESI): m/z calcd. for 
C19H39O3Si2+ [M+H]+ 371.2432; found 371.2425. 
(1S,3R)-3-(tert-Butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (4c). A suspension of m-
CPBA (77%, 13.640 g, 60.83 mmol) in anhydrous CH2Cl2 (30 mL) at rt under N2 was added to a stirred 
solution of 7c (5.849 g, 24.33 mmol) in anhydrous CH2Cl2 (20 mL) and the mixture was stirred at rt for 
15 hours. The mixture was filtered and the organic phase was washed with saturated Na2S2O3 (35 mL), 
saturated NaHCO3 (2 × 15 mL), dried (MgSO4) and the solvent was removed to give the title compound 
(4c)9a as a yellow oil (6.048 g, 97%). IR (film): 3454, 3318, 3083, 2962, 2930, 2895, 2860 cm-1. 1H 
NMR (CDCl3, 400 MHz): δ 4.58-4.54 (m, 1H), 3.89-3.83 (m, 0.4H), 3.72-3.65 (m, 0.6 H), 2.95 (ddd, J 
= 8.0, 4.1, 2.0 Hz, 1H), 2.71-2.63 (m, 2H), 2.38 (d, J = 2.1 Hz, 0.4H), 2.47 (d, J = 2.1 Hz, 0.6H), 1.98-
1.81 (m, 2H), 0.81 (s, 9H), 0.08 (s, 1.2H), 0.08 (s, 1.8H), 0.06 (s, 1.2H), 0.05 (s, 1.8H). 13C NMR 
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(CDCl3, 101 MHz): δ 84.5, 84.4, 73.6, 73.5, 69.7, 68.2, 61.7, 61.3, 55.2, 54.3, 44.9, 44.4, 42.4, 41.9, 
25.8, 18.2, 18.1, -4.3, -4.4, -5.0, -5.1. HRMS (ESI): m/z calcd. for C13H25O3Si+ [M+H]+ 257.1568; found 
257.1559. 
(1S,3R)-3-(tert-Butyldiphenylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (4d). A suspension of m-
CPBA (77%, 0.516 g, 2.26 mmol) in anhydrous CH2Cl2 (3 mL) at rt under N2 was added to a stirred 
solution of 7d (0.275 g, 0.754 mmol) in anhydrous CH2Cl2 (2 mL) and the mixture was stirred at rt for 
2.5 h. After filtration the organic phase was washed with saturated Na2S2O3 (5 mL), saturated NaHCO3 
(2 × 15 mL) and dried (MgSO4). Solvent removal gave the title compound (4d) as a pale yellow oil 
(0.290 g, 99%). IR (film): 3447, 3287, 2960, 2930, 2891, 2857, 2117 cm-1. 1H NMR (CDCl3, 400 MHz): 
δ 7.77-7.66 (m, 4H), 7.47-7.35 (m, 6H), 4.67-4.59 (m, 1H), 4.10-4.04 (m, 0.4H), 3.84-3.76 (s, 0.6H), 
3.05 (dd, J = 6.6, 3.7 Hz, 0.4H), 2.98 (td, J = 4.3, 2.8 Hz, 0.6H), 2.79-2.68 (m, 2H), 2.37 (d, J = 2.1 Hz, 
1H), 2.02-1.85 (m, 3H), 1.08 (s, 9H). 13C NMR (CDCl3, 101 MHz): δ 136.2, 136.1, 135.9, 133.2, 133.2, 
133.2, 130.10, 130.1, 130.0, 127.9, 127.8, 127.6, 127.5, 84.1, 84.1, 74.3, 74.2, 68.8, 66.7, 61.9, 61.7, 
55.2, 54.4, 45.0, 43.9, 42.7, 41.7, 27.0, 19.4. HRMS (ESI): m/z calcd. for C23H28NaO3Si+ [M+Na]+ 
403.1700; found 403.1702. 
(1S,3R)-1-(Oxiran-2-yl)-3-(triisopropylsilyloxy)pent-4-yn-1-ol (4e). A solution of 7e (4.900 g, 
17.34 mmol) in anhydrous CH2Cl2 (7 mL) was added to a suspension of m-CPBA (77%, 9.500 g, 42.48 
mmol) in anhydrous CH2Cl2 (33 mL) at rt under N2 and the mixture was stirred at rt for 15 h. After 
filtration the organic phase was washed with saturated Na2S2O3 (20 mL), saturated NaHCO3 (2 × 20 mL) 
and dried (MgSO4). Solvent removal gave the title compound (4e)9a as a pale yellow oil (4.920 g, 95%). 
IR (film): 3447, 3310, 2944, 2867, 2109 cm-1. 1H NMR (CDCl3, 400 MHz): δ 4.80-4.74 (m, 1H), 4.09-
4.02 (m, 0.4H), 3.87-3.79 (m, 0.6H), 3.11-3.04 (m, 1H), 2.84-2.79 (m, 1H), 2.78-2.74 (m, 1H), 2.49 (d, 
J = 2.1 Hz, 0.4H), 2.47 (d, J = 2.1 Hz, 0.6H), 2.10-1.91 (m, 2H), 1.13-1.04 (m, 21H). 13C NMR (CDCl3, 
101 MHz): δ 84.7, 84.6, 73.6, 73.6, 69.5, 67.5, 61.5, 61.2, 55.4, 54.4, 45.0, 44.2, 42.8, 42.1, 18.1, 18.1, 
12.4, 12.3. HRMS (ESI): m/z calcd. for C16H31O3Si+ [M+H]+ 299.2037; found 299.2035. 
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(3R,5S)-5-Hydroxy-5-(oxiran-2-yl)pent-1-yn-3-yl benzoate (4f). A solution of 7f (0.500 g, 2.17 
mmol, 91:9 mixture of monobenzoylated regioisomers) in anhydrous CH2Cl2 (3 mL) was added to a 
suspension of m-CPBA (77%, 1.460 g, 6.51 mmol) in anhydrous CH2Cl2 (2 mL) at rt under N2 and the 
mixture was stirred at rt for 15 h. After filtration the organic phase was washed with saturated Na2S2O3 
(7 mL), saturated NaHCO3 (2 × 10 mL) and dried (MgSO4). Solvent removal gave an oily residue that 
was purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 50:50 (gradient 
elution)] to give the title compound (4f) as a pale yellow oil (0.465 g, 87%, single monobenzoylated 
regioisomer). IR (film): 3446, 3288, 3063, 2997, 2929, 2121, 1719 cm-1. 1H NMR (CDCl3, 400 MHz): δ 
8.07-8.01 (m, 2H), 7.60-7.53 (m, 1H), 7.44 (t, J = 7.7 Hz, 2H), 5.89-5.81 (m, 1H), 4.18 (ddd, J = 7.9, 
4.8, 3.3 Hz, 0.4H), 3.86 (dt, J = 9.0, 4.6 Hz, 0.6H), 3.09 (ddd, J = 7.4, 6.0, 2.9 Hz, 1H), 2.88-2.81 (m, 
1H), 2.79-2.74 (m, 0.6H), 2.72 (dd, J = 5.0, 4.0 Hz, 0.4H), 2.56 (t, J = 1.9 Hz, 1H), 2.32-2.13 (m, 2H). 
13C NMR (CDCl3, 101 MHz): δ 165.4, 133.5, 133.4, 129.9, 129.9, 129.6, 129.6, 128.6, 128.5, 80.7, 
80.6, 74.9, 74.8, 68.5, 65.9, 62.1, 62.0, 55.1, 54.2, 45.1, 43.7, 39.3, 38.4. HRMS (ESI): m/z calcd. for 
C14H15O4+ [M+H]+ 247.0965; found 247.0966. 
(1S,3R)-3-(tert-Butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-ynyl acetate (4g). NEt3 (3.80 mL, 
27.89 mmol) was added dropwise to a solution of 4c (5.499 g, 21.45 mmol) and a catalytic amount of 
DMAP in anhydrous CH2Cl2 (50 mL) at 0 ºC under N2. Ac2O (2.40 mL, 25.74 mmol) was added 
dropwise at 0-5 ºC and the mixture was allowed to warm to rt and stirred for 1 h. Saturated NH4Cl (35 
mL) was added slowly and the mixture was stirred for 10 min. After partitioning the aqueous phase was 
extracted with CH2Cl2 (20 mL) and the combined organic phases were washed with saturated NaHCO3 
(30 mL). The aqueous phase was extracted with CH2Cl2 (20 mL) and the combined organic phases were 
dried (MgSO4) and the solvent was removed to give the title compound9a (4g) as a pale yellow oil (6.300 
g, 98%). IR (film): 3295, 3075, 2970, 2947, 2903, 2873, 1750 cm-1. 1H NMR (CDCl3, 400 MHz): δ 
5.07-4.99 (m, 1H), 4.54-4.48 (m, 1H), 3.16 (ddd, J = 5.7, 4.1, 2.6 Hz, 0.6H), 3.05 (ddd, J = 4.9, 3.9, 2.7 
Hz, 0.4H), 2.82 (dd, J = 4.9, 4.2 Hz, 0.6H), 2.77-2.70 (m, 0.8H), 2.67 (dd, J = 4.8, 2.7 Hz, 0.6H), 2.44 
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(d, J = 2.1 Hz, 0.6H), 2.43 (d, J = 2.1 Hz, 0.4H), 2.08 (s, 1.2H), 2.06 (s, 1.8H), 2.16-1.97 (m, 2H), 0.90 
(s, 9H), 0.15 (s, 1.8H), 0.14 (s, 1.2H), 0.12 (s, 1.8H), 0.12 (s, 1.2H). 13C NMR (CDCl3, 101 MHz): δ 
171.1, 85.1, 74.5, 74.4, 72.0, 70.9, 60.8, 54.1, 53.2, 46.3, 40.9, 40.7, 26.8, 22.1, 22.0, 19.2, –3.5, –4.1. 
HRMS (ESI): m/z calcd. for C15H27O4Si+ [M+H]+ 299.1674; found 299.1665. 
(5R,7S)-5-Ethynyl-2,2,3,3,10,10-hexamethyl-7-(oxiran-2-yl)-9,9-diphenyl-4,8-dioxa-3,9-
disilaundecane (4h). TBDPSCl (0.17 mL, 0.66 mmol) was added dropwise to a solution of 4c (0.085 g, 
0.33 mmol) and imidazole (0.050 g, 0.73 mmol) in anhydrous THF (3 mL) at 0 ºC under N2, and the 
mixture was warmed to 30 ºC and stirred for 48 h. A 22% solution of NH4Cl (5 mL) was added slowly 
and the mixture was stirred for 10 min. MTBE (15 mL) and H2O (5 mL) were added and the mixture 
was stirred for 10 min and partitioned. The organic phase was dried (MgSO4), and the solvent was 
removed. The resulting oily residue was purified by flash chromatography (silica gel, hexanes-AcOEt 
98:2) to give the title compound (4h) as a colorless oil (0.130 g, 79%). IR (film): 3309, 3049, 2956, 
2930, 2892, 2857 cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.73-7.68 (m, 4H), 7.44-7.32 (m, 6H), 4.70 (ddd, 
J = 7.6, 6.9, 2.1 Hz, 0.4H), 4.57 (dt, J = 6.8, 2.1 Hz, 0.6H), 3.69-3.57 (m, 1H), 3.11-3.04 (m, 0.6H), 
2.90-2.84 (m, 0.4H), 2.67 (dd, J = 4.8, 4.3 Hz, 0.6H), 2.46 (dd, J = 4.9, 2.7 Hz, 0.6H), 2.32-2.28 (m, 
0.6H), 2.20 (d, J = 2.1 Hz, 0.4H), 1.99 (m, 1H), 1.91-1.82 (m, 1H), 1.08 (s, 9H), 0.85 (s, 9H), 0.12 (s, 
0.6H), 0.09 (s, 2.4H), 0.07 (s, 0.6H), 0.07 (s, 2.4H). 13C NMR (CDCl3, 101 MHz): δ 136.2, 136.1, 136.1, 
136.0, 134.0, 133.8, 133.7, 133.4, 130.0, 129.9, 129.8, 129.7, 127.8, 127.7, 127.7, 127.5, 85.1, 84.7, 
73.1, 73.0, 72.9, 71.3, 60.1, 60.0, 55.6, 54.5, 46.5, 45.2, 44.6, 43.5, 27.2, 27.1, 25.9, 25.8, 19.6, 19.5, 
18.3, 18.2, -4.4, -4.5, -4.9. HRMS (ESI): m/z calcd. for C29H46NO3Si2+ [M+NH4]+ 512.3011; found 
512.3005. 
(5R,7S)-5-Ethynyl-2,2,9,9,10,10-hexamethyl-7-(oxiran-2-yl)-3,3-diphenyl-4,8-dioxa-3,9-
disilaundecane (4i). A solution of TBSCl (0.230 g, 1.53 mmol) in anhydrous THF (2 mL) was added 
dropwise to a solution of 4d (0.220 g, 0.58 mmol) and imidazole (0.110 g, 1.62 mmol) in anhydrous 
THF (3 mL) at 0 ºC under N2, and the mixture was warmed to 30 ºC and stirred for 24 h. A 22% 
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solution of NH4Cl (5 mL) was added slowly and the mixture was stirred for 10 min. MTBE (15 mL) and 
H2O (5 mL) were added and the mixture was stirred for 10 min and partitioned. The organic phase was 
dried (MgSO4), and the solvent was removed. The resulting oily residue was purified by flash 
chromatography [silica gel, hexanes-AcOEt, from 99:1 to 90:10 (gradient elution)] to give the title 
compound (4i) as a colorless oil (0.203 g, 71%). IR (film): 3307, 3071, 2955, 2928, 2892, 2856 cm-1. 1H 
NMR (CDCl3, 300 MHz): δ 7.89-7.78 (m, 4H), 7.60-7.46 (m, 6H), 4.71-4.62 (m, 1H), 3.93 (dt, J = 8.0, 
4.1 Hz, 0.3H), 3.64-3.54 (m, 0.7H), 3.07-2.96 (m, 1H), 2.88 (dd, J = 4.8, 4.2 Hz, 0.7H), 2.80 (dd, J = 
5.4, 4.2 Hz, 0.3H), 2.74 (dd, J = 5.4, 2.8 Hz, 0.3H), 2.66 (dd, J = 4.9, 2.8 Hz, 0.7H), 2.50 (d, J = 2.1 
Hz, 0.3H), 2.48 (d, J = 2.1 Hz, 0.7H), 2.20-2.00 (m, 2H), 1.22 (bs, 9H), 0.87 (bs, 6H), 0.84 (s, 3H), 0.19 
(s, 2H), 0.14 (s, 1H), 0.11 (s, 1H), 0.04 (s, 2H).13C NMR (CDCl3, 101 MHz): δ 136.2, 136.1, 135.9, 
135.9, 133.5, 133.4, 130.0, 129.9, 129.8, 129.7, 127.8, 127.8, 127.6, 127.5, 84.5, 84.4, 74.1, 74.0, 72.4, 
68.6, 61.8, 56.0, 54.7, 45.0, 44.7, 43.6, 43.0, 27.0, 25.9, 25.9, 19.4, 18.1, 18.1, -4.4, -4.3, -5.1, -5.3. 
HRMS (ESI): m/z calcd. for C29H42NaO3Si2+ [M+Na]+ 517.2565; found 517.2572. 
(1S,3R)-1-(Oxiran-2-yl)-3-(triisopropylsilyloxy)pent-4-yn-1-yl acetate (4j). NEt3 (0.29 mL, 2.15 
mmol) was added dropwise to a solution of 4e (0.495 g, 1.66 mmol) and a catalytic amount of DMAP in 
anhydrous CH2Cl2 (5 mL) at 0 ºC under N2. Ac2O (0.19 mL, 1.99 mmol) was added dropwise at 0 ºC 
and the mixture was allowed to warm to rt and stirred for 1 h. Saturated NH4Cl (5 mL) was added 
slowly and the mixture was stirred for 10 min. After partitioning the aqueous phase was extracted with 
CH2Cl2 (5 mL) and the organic phases were combined and washed with saturated NaHCO3 (2 × 5 mL). 
The combined organic phases were dried (MgSO4), and solvent removal gave the title compound (4j) as 
a yellow oil (0.508 g, 90%). IR (film): 3301, 3064, 2944, 2867, 2118 cm-1. 1H NMR (CDCl3, 400 MHz): 
δ 5.12-5.06 (m, 1H), 4.64-4.55 (m, 1H), 3.17 (ddd, J = 5.6, 4.2, 2.7 Hz, 0.6H), 3.07 (ddd, J = 4.4, 3.7, 
2.6 Hz, 0.4H), 2.83 (dd, J = 4.9, 4.2 Hz, 0.6H), 2.75 (m, 0.8H), 2.68 (dd, J = 4.9, 2.6 Hz, 0.6H), 2.44 
(m, 1H), 2.15-1.99 (m, 5H), 1.18-0.98 (m, 21H). 13C NMR (CDCl3, 101 MHz): δ 170.1, 84.1, 73.5, 73.4, 
70.9, 69.8, 60.0, 59.9, 53.2, 52.2, 45.3, 40.2, 39.7, 21.0, 20.9, 18.1, 18.0, 17.8, 12.4, 12.3, 12.2. HRMS 
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(ESI): m/z calcd. for C18H33O4Si+ [M+H]+ 341.2143; found 341.2141. 
(3R,5S)-5-(tert-Butyldimethylsilyloxy)-5-(oxiran-2-yl)pent-1-yn-3-yl benzoate (4k). A solution of 
TBSCl (0.464 g, 3.08 mmol) in anhydrous THF (2 mL) was added dropwise to a solution of 4f (0.400 g, 
1.62 mmol) and imidazole (0.330 g, 4.86 mmol) in anhydrous THF (3 mL) at 0 ºC under N2, and the 
mixture was warmed to 30 ºC and stirred for 24 h. A 22% solution of NH4Cl (5 mL) was added slowly 
and the mixture was stirred for 10 min. MTBE (15 mL) and H2O (5 mL) were added and the mixture 
was stirred for 10 min and partitioned. The organic phase was dried (MgSO4), and the solvent was 
removed. The resulting oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, 
from 95:5 to 90:10 (gradient elution)] to give the title compound (4k) as a white waxy solid (0.390 g, 
67%). IR (film): 3270, 3066, 2954, 2928, 2886, 2856, 2121, 1724 cm-1. 1H NMR (CDCl3, 300 MHz): δ 
8.09-8.03 (m, 2H), 7.62-7.53 (m, 1H), 7.48-7.41 (m, 2H), 5.83-5.75 (m, 1H), 3.90 (dt, J = 7.4, 4.6 Hz, 
0.3H), 3.60 (ddd, J = 8.7, 6.8, 4.4 Hz, 0.7H), 3.02-2.80 (m, 1H), 2.70-2.66 (m, 0.6H), 2.53 (m, 1.4H), 
2.29-2.18 (m, 1H), 2.14-2.03 (m, 1H), 0.93 (bs, 9H), 0.16 (s, 1.5H), 0.14 (s, 3H), 0.09 (s, 1.5H). 13C 
NMR (CDCl3, 101 MHz): δ 165.3, 165.2, 133.4, 133.4, 129.9, 129.8, 129.7, 128.6, 128.5, 80.8, 74.8, 
74.7, 72.0, 68.6, 62.1, 61.8, 55.7, 54.5, 45.2, 45.0, 40.1, 39.6, 26.0, 25.9, 18.2, -4.2, -4.3, -4.9, -5.1. 
HRMS (ESI): m/z calcd. for C20H32NO4Si+ [M+NH4]+ 378.2095; found 378.2099. 
General procedure for non-catalytic 5-exo cyclization  
Strictly deoxygenated anhydrous THF (76 mL) was added to a mixture of Cp2TiCl2 (1.711 g, 6.87 
mmol) and activated Zn powder (1.800 g, 27.48 mmol) under N2 and the suspension was stirred at rt 
until it turned lime green. This suspension was then added slowly to a solution of 4b (0.850 g, 2.29 
mmol) over 3 h and the mixture was stirred for 15 h at rt. A 22% solution of NH4Cl (60 mL) was added 
slowly and the mixture was stirred for 2 h, filtered and the solvent was removed. AcOEt (100 mL) was 
added and the mixture was stirred for 10 min. The mixture was partitioned and the aqueous phase was 
extracted with AcOEt (2 × 50 mL). The combined organic phases were dried (MgSO4) and the solvent 
was removed. The resulting oily residue was purified by flash chromatography [silica gel, hexanes-
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AcOEt, from 95:5 to 80:20 (gradient elution)] to give the title compound as a pale yellow oil (0.424 g, 
50%). 
((1R,3R,5S)-3,5-Bis(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methanol (5b).12 [α]D25 –
30.4 (c 1.0, CHCl3). IR (film): 3460, 3070, 2956, 2930, 2887, 2858 cm-1. 1H NMR (CDCl3, 400 MHz): δ 
5.21 (t, J = 2.3 Hz, 1H), 5.01 (t, J = 2.3 Hz, 1H), 4.33 (ddd, J = 9.3, 4.8, 2.3 Hz, 1H), 4.00 (ddd, J = 
10.1, 8.0, 6.2 Hz, 1H), 3.82-3.69 (m, 2H), 2.66-2.59 (m, 1H), 2.24 (dd, J = 11.6, 6.2 Hz, 1H), 1.67-1.61 
(m, 1H), 0.92 (s, 9H), 0.89 (s, 9H), 0.10 (s, 3H), 0.09 (s, 6H), 0.08 (s, 3H). 13C NMR (CDCl3, 101 
MHz): δ 152.1, 108.4, 72.4, 71.0, 63.0, 53.2, 43.9, 26.0, 25.9, 18.4, 18.1, -4.1, -4.4, -4.6, -4.7. HRMS 
(ESI): m/z calcd. for C19H41O3Si2+ [M+H]+ 373.2589; found 373.2592. 
(1S,2R,4R)-4-(tert-Butyldimethylsilyloxy)-2-hydroxymethyl-3-methylenecyclopentyl acetate 
(5g).9a [α]D25 –43.5 (c 1.0, CHCl3). IR (film): 3462, 3083, 2955, 2930, 2887, 2858, 1734 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ 5.24 (t, J = 2.3 Hz, 1H), 5.1 (t, J = 2.3 Hz, 1H), 4.99 (dt, J = 8.4, 6.4 Hz, 1H), 
4.42 (m, 1H), 3.70 (d, J = 5.8 Hz, 2H), 2.84-2.73 (m, 1H), 2.48-2.38 (m, 1H), 2.07 (s, 3H), 1.81-1.69 
(m, 1H), 0.91 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 171.9, 151.7, 109.0, 
73.5, 72.7, 63.7, 51.0, 40.5, 25.9, 21.3, 18.3, –4.5, –4.7. HRMS (ESI): m/z calcd. for C15H29O4Si+ 
[M+H]+ 301.1830; found 301.1816. 
((1R,3R,5S)-3-(tert-Butyldimethylsilyloxy)-5-(tert-butyldiphenylsilyloxy)-2-
methylenecyclopentyl)methanol (5h). [α]D25 –18.3 (c 1.0, CHCl3). IR (ATR): 3454, 3070, 2955, 2929, 
2888, 2856 cm-1. 1H NMR (CDCl3, 400 MHz): δ 7.73-7.65 (m, 4H), 7.47-7.35 (m, 6H), 5.17 (t, J = 2.3 
Hz, 1H), 4.99 (t, J = 2.3 Hz, 1H), 4.18-4.09 (m, 1H), 4.02 (dt, J = 9.5, 6.7 Hz, 1H), 3.60 (dd, J = 11.1, 
4.8 Hz, 1H), 3.49 (dd, J = 11.1, 4.5 Hz, 1H), 2.75-2.71 (m, 1H), 2.01-1.92 (m, 1H), 1.63 (dt, J = 11.4, 
9.5 Hz, 1H), 1.06 (s, 9H), 0.86 (s, 9H), 0.00 (s, 3H), –0.02 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 
152.4, 136.0, 134.3, 134.0, 131.0, 130.0, 129.9, 128.0, 127.9, 127.8, 126.7, 108.2, 72.4, 71.6, 62.7, 53.6, 
43.7, 27.1, 26.0, 19.3, 18.3, -4.5, -4.7. HRMS (ESI): m/z calcd. for C29H48NO3Si2+ [M+NH4]+ 514.3167; 
found 514.3165. 
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(1R,3R,4S)-4-(tert-Butyldimethylsilyloxy)-3-hydroxymethyl-2-methylenecyclopentyl benzoate 
(5k). [α]D25 –26.4 (c 1.0, CHCl3). IR (ATR): 3503, 3064, 2954, 2929, 2885, 2856, 1718 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ 8.10-8.04 (m, 2H), 7.61-7.53 (m, 1H), 7.49-7.40 (m, 2H), 5.66-5.61 (m, 1H), 5.37 
(t, J = 2.4 Hz, 1H), 5.19 (t, J = 2.4 Hz, 1H), 4.19-4.10 (m, 1H), 3.86-3.80 (m, 2H), 2.81-2.71 (m, 1H), 
2.64-2.55 (m, 1H), 1.83 (dt, J = 12.7, 8.4 Hz, 1H), 0.90 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H). 13C NMR 
(CDCl3, 101 MHz): δ 166.5, 147.7, 133.1, 130.3, 129.8, 128.5, 112.0, 74.2, 72.2, 62.5, 53.5, 40.5, 25.9, 
18.0, -4.3, -4.8. HRMS (ESI): m/z calcd. for C20H31O4Si+ [M+H]+ 363.1986; found 363.1988. 
Catalytic 5-exo cyclization of 4g 
Strictly deoxygenated anhydrous THF (15 mL) was added to a mixture of IrCl(CO)(PPh3)2 (0.260 g, 
0.34 mmol) and manganese powder (0.368 g, 6.70 mmol). A solution of 2,4,6-collidine (3.5 mL, 26.8 
mmol) and 4g (1.000 g, 3.35 mmol) in strictly deoxygenated anhydrous THF (22 mL) was added at rt. 
TMSCl (1.7 mL, 13.4 mmol) was added followed by a solution of Cp2TiCl2 (0.167 g, 0.67 mmol) in 
strictly deoxygenated anhydrous THF (12 mL) and the mixture was stirred for 4 h under H2 (4 bar) at rt. 
Water (5 mL) was added and the mixture was stirred for 10 min and filtered through Celite®. The pad 
was washed with MTBE (20 mL) and the organic phases were combined and acidified to pH=2 with 2 
M HCl. The mixture was stirred for 15 min and the phases were separated. The organic phase was 
washed with H2O (20 mL) and dried (Na2SO4). The solvent was removed and the resulting oily residue 
was purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 60:40 (gradient 
elution)] to give the title compound (5g) as a pale yellow oil (0.582 g, 58%). 
((1R,3R,5S)-5-Acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-
nitrobenzoate (5l). NEt3 (0.65 ml, 4.62 mol) was added dropwise to a solution of 5g (1.000 g, 3.33 
mmol) and a catalytic amount of DMAP in anhydrous CH2Cl2 (9 mL) at 0 ºC under N2. A solution of 
p-nitrobenzoyl chloride (0.740 g, 3.99 mmol) in anhydrous CH2Cl2 (4 mL) was added dropwise at 0–5 
ºC. The mixture was allowed to warm to rt and was stirred for 2 h. Saturated NH4Cl (10 mL) was added 
slowly and the mixture was stirred for 15 min. The mixture was partitioned and the organic phase was 
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washed with H2O and dried (Na2SO4). The solvent was removed and the resulting oily residue was 
purified by flash chromatography (silica gel, hexanes-AcOEt 90:10) to give the title compound (5l) as 
white solid (1.102 g, 74% yield). Mp 83 ºC. [α]D25 –8.6 (c 1.0, CHCl3). IR (ATR): 2981, 2959, 2944, 
2884, 2858, 1730, 1713 cm-1. 1H NMR (CDCl3, 400 MHz): δ 8.31-8.13 (m, 4H), 5.27 (t, J = 2.3 Hz, 
1H), 5.13 (t, J = 2.3 Hz, 1H), 5.05 (dt, J = 8.4, 6.6 Hz, 1H), 4.48 (m, 3H), 3.18-3.08 (m, 1H), 2.59-2.44 
(m, 1H), 1.99 (s, 3H), 1.79-1.64 (m, 1H), 0.91 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H). 13C NMR (CDCl3, 101 
MHz): δ 170.9, 164.6, 150.7, 150.5, 135.5, 130.8, 123.7, 110.1, 73.2, 72.5, 66.3, 46.9, 40.5, 25.9, 21.2, 
18.3, –4.5, –4.6. HRMS (ESI): m/z calcd. for C22H32NO7Si+ [M+H]+ 450.1943; found 450.1947. 
((1R,3R,5S)-5-Acetoxy-3-hydroxy-2-methylenecyclopentyl)methyl 4-nitrobenzoate (5m). (+)-
Camphorsulfonic acid ((+)-CSA, 0.034 g, 0.15 mmol) was added to a solution of 5l (0.660 g, 1.47 
mmol) in anhydrous MeOH (7 mL) at rt under N2. The mixture was stirred for 2 h and was then cooled 
to 0 ºC and stirred for 1 h. The pH was adjusted to 6.5 by adding 1% NaHCO3 solution. The MeOH was 
removed in vacuo and the aqueous layer was extracted with MTBE. The organic phase was dried 
(Na2SO4), the solvent was removed and the resulting oily residue was purified by flash chromatography 
(silica gel, hexanes-AcOEt 60:40) to give the title compound (5m) as a white solid (0.439 g, 89%). Mp 
73 ºC. [α]D25 –32.7 (c 1.0, CHCl3). IR (KBr): 3460, 3109, 3074, 3050, 2990, 2927, 1722 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ 8.26-8.22 (m, 4H), 5.44 (bs, 1H), 5.25 (d, J = 1.5 Hz, 1H), 5.17 (q, J = 5.5 Hz, 
1H), 4.56-4.54 (m, 1H), 4.52–4.43 (m, 1H), 4.42–4.30 (m, 1H), 3.21-3.18 (m, 1H), 2.53-2.49 (m, 1H), 
2.02 (s, 3H), 1.85 (dt, J = 12.4, 5.5 Hz, 1H). 13C NMR (CDCl3, 101 MHz): δ 170.6, 164.6, 151.3, 150.8, 
135.4, 130.8, 123.8, 112.3, 74.8, 73.2, 65.9, 47.9, 40.1, 21.3. HRMS (ESI): m/z calcd. for C16H21N2O7+ 
[M+NH4]+ 353.1343; found 353.1328. 
((1R,3S,5S)-5-Acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl 4-
nitrobenzoate (13). A mixture of 2-amino-6-chloropurine (7.380 g, 43.54 mmol) and 
triphenylphosphine (11.400 g, 43.54 mmol) in anhydrous THF (927 mL) at rt under N2 was stirred for 
15 min. After cooling to -10 ºC, diisopropyl azodicarboxylate (DIAD, 8.60 mL, 43.54 mmol) was added 
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dropwise and the mixture was stirred for 10 min. A solution of 5m (7.300 g, 21.77 mmol) in anhydrous 
THF (160 mL) was added over 1 h. The mixture was stirred for 3 h at -10 ºC and was then allowed to 
warm to rt, filtered and the residue was washed with THF (109 mL). The solvent was removed and the 
resulting oily residue was purified by crystallization from isopropanol (440 mL) to afford the title 
compound as a pale yellow solid (6.510 g, 61%). Mp 113 ºC. [α]D25 +9.8 (c 1.0, CHCl3). IR (KBr): 
3498, 3382, 3213, 3082, 2970, 1728, 1715 cm-1. 1H NMR (CDCl3, 400 MHz): δ 8.28 (dd, J = 20.6, 8.9 
Hz, 4H), 7.80 (s, 1H), 5.58–5.40 (m, 2H), 5.35-5.30 (m, 1H), 4.91 (bs, 1H), 4.85 (dd, J = 11.4, 9.3 Hz, 
1H), 4.62 (dd, J = 11.4, 6.3 Hz, 1H), 3.28-3.24 (m, 1H), 2.85 (ddd, J = 14.3, 10.6, 5.2 Hz, 1H), 2.42 (dd, 
J = 14.3, 8.1 Hz, 1H), 2.08 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ 170.3, 165.0, 158.9, 153.1, 151.8, 
150.8, 146.2, 141.9, 135.2, 130.9, 125.9, 123.8, 113.6, 74.6, 65.9, 57.4, 48.7, 35.5, 21.3. HRMS (ESI): 
m/z calcd. for C21H20ClN6O6+ [M+H]+ 487.1127; found 487.1132. 
 ((1R,3S,5S)-5-Acetoxy-3-(2-amino-6-oxo-1H-purin-9(6H)-yl)-2-methylenecyclopentyl)methyl 4-
nitrobenzoate (14). A solution of 13 (6.300 g, 12.94 mmol) in formic acid 80% (126 mL) at 50 ºC 
under N2 was stirred for 9 h. The solvent was removed, H2O (72 mL) was added and the suspension was 
stirred for 18 h at rt. The suspension was filtered and the solid was dried to afford the title compound 
(14) as a yellow solid (5.590 g, 92%). Mp 282 ºC. [α]D25 +2.9 (c 1.0, DMSO). IR (KBr): 3408, 3315, 
3210, 3110, 2934, 2868, 1728, 1706 cm-1. 1H NMR (DMSO-d6, 400 MHz) δ: 11.08 (bs, 1H), 8.37 (d, J 
= 8.8 Hz, 2H), 8.24 (d, J = 8.8 Hz, 2H), 7.74 (s, 1H), 6.66 (bs, 2H), 5.42-5.35 (m, 1H), 5.35-5.31 (m, 
1H), 5.27 (bs, 1H), 4.67 (bs, 1H), 4.59-4.55 (m, 2H), 3.17-3.10 (m, 1H), 2.70 (ddd, J = 13.6, 11.3, 5.3 
Hz, 1H), 2.34-2.25 (m, 1H), 2.01 (s, 3H). 13C NMR (DMSO-d6, 101 MHz) δ: 169.9, 164.3, 156.8, 153.5, 
151.2, 150.3, 147.8, 136.1, 135.1, 130.7, 123.9, 116.5, 111.2, 74.1, 65.6, 55.2, 47.8, 35.2, 21.0. HRMS 
(ESI): m/z calcd. for C21H21N6O7+ [M+H]+ 469.1466; found 469.1461.  
2-Amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1H-purin-6(9H)-
one monohydrate (1). A solution of MeONa (30%, 4.10 mL, 22.20 mmol) was added dropwise to a 
solution of 14 (5.200 g, 11.10 mmol) in anhydrous MeOH (40 mL) at rt under N2. The mixture was 
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stirred for 30 min at rt and cooled to 0 ºC. MTBE (52 mL) was added and the mixture was neutralized 
(pH=7) with HCl. The phases were separated and the aqueous layer was extracted with MTBE (50 mL). 
The volume of the aqueous phase was reduced to 45 mL by distillation. The suspension was heated at 
85 ºC and was slowly cooled to rt and stirred for 15 h. After filtration the isolated solid was dried under 
vacuum to afford the title compound (1) as a white solid with a 6.5% water content (as determined by 
Karl Fischer titration) and 98.8% HPLC purity (2.370 g, 72% yield). This white solid 15a was 
recrystallized from water to afford 1 (2.102 g, 64% overall yield, 99.47 % HPLC purity) with a 6.7% 
water content (as determined by Karl Fischer titration). Mp 248 ºC. [α]D25 +35.0 (c 0.4, H2O). IR (ATR): 
3445, 3361, 3296, 3175, 3113, 2951, 2858, 2626, 1709 cm-1. 1H NMR (DMSO-d6, 400 MHz) δ: 10.59 
(s, 1H), 7.66 (s, 1H), 6.42 (bs, 2H), 5.36 (ddt, J = 10.6, 7.8, 2.7 Hz, 1H), 5.10 (dd, J = 2.7, 2.2 Hz, 1H), 
4.87 (d, J = 3.1 Hz, 1H), 4.84 (t, J = 5.3 Hz, 1H), 4.56 (t, J = 2.4 Hz, 1H), 4.23 (m, 1H), 3.53 (m, 2H), 
2.52 (m, 1H), 2.22 (ddd, J = 12.6, 10.8, 4.6 Hz, 1H), 2.04 (ddt, J = 12.6, 7.7, 1.9 Hz, 1H). 13C NMR 
(DMSO-d6, 101 MHz) δ: 156.9, 153.5, 151.5, 151.3, 136.0, 116.2, 109.3, 70.4, 63.1, 55.2, 54.1, 39.2. 
HRMS (ESI): m/z calcd. for C12H16N5O3+ [M+H]+ 278.1253; found 278.1262. 
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